Basics Atara Biotherapeutics, Inc. Atara Biotherapeutics Inc is engaged in the development of pharmaceutical products. The company's focus lies on developing therapies addressing serious-life threatening diseases in the United States. IPO Date: October 16, 2014 Sector: Healthcare Industry: Biotech Market Cap: $90.67M Activated in VL: True Average Daily Range Avg Daily Range: $0.62 | 3.87% Avg Daily Range (30 D): $0.28 | 2.36% Avg Daily Range (90 D): $0.28 | 3.03% Institutional Daily Volume Avg Daily Volume: .68M Avg Daily Volume (30 D): .04M Avg Daily Volume (90 D): .04M Trade Size Avg Trade Size (Sh.): 142 Avg Trade Size (Sh.) (30 D): 82 Avg Trade Size (Sh.) (90 D): 86 Institutional Trades Total Inst.Trades: 2,721 Avg Inst. Trade: $2.22M Avg Inst. Trade (30 D): $.52M Avg Inst. Trade (90 D): $.52M Avg Inst. Trade Volume: .01M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2M Avg Closing Trade (30 D): $4.55M Avg Closing Trade (90 D): $4.55M Avg Closing Volume: 6.14K     News Jan 30, 2025 @ 10:39 PM Wolf Haldenstein Adler Freeman & Herz LLP announce... Source: N/A Nov 20, 2024 @ 9:47 PM FUJIFILM Diosynth Biotechnologies Celebrates the E... Source: Fujifilm Diosynth Biotechnologies Jul 17, 2024 @ 11:03 AM Presenting on the Emerging Growth Conference 73 Da... Source: N/A May 23, 2024 @ 2:06 PM Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease... Source: Zacks Equity Research May 22, 2024 @ 3:12 PM GSK Studies on Depemokimab for Severe Asthma Meet ... Source: Zacks Equity Research Financials   TTM Q1 2025 Q4 2024 Basic EPS $.2 $3.53 $-.07 Diluted EPS $.19 $3.5 $-.07 Revenue $ 17.58M $ 98.15M $ 32.75M Gross Profit $ $ $ Net Income / Loss $ 2.39M $ 38.01M $ -12.69M Operating Income / Loss $ 3.2M $ 38.8M $ -12.2M Cost of Revenue $ $ $ Net Cash Flow $ 2.92M $ -11.19M $ -21.42M PE Ratio 67.95     Splits Jun 20, 2024:   1:25